🚀 VC round data is live in beta, check it out!
Qiagen Valuation Multiples
Discover revenue and EBITDA valuation multiples for Qiagen and similar public comparables like Revvity, ALS, Bangkok Dusit Medical Services, Pro Medicus and more.
Qiagen Overview
About Qiagen
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Founded
1980
HQ
Employees
5.7K
Website
Financials (LTM)
EV
$11B
Qiagen Financials
Qiagen reported last 12-month revenue of $2B and EBITDA of $773M.
In the same LTM period, Qiagen generated $1B in gross profit, $773M in EBITDA, and $523M in net income.
Revenue (LTM)
Qiagen P&L
In the most recent fiscal year, Qiagen reported revenue of $2B and EBITDA of $757M.
Qiagen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 67% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $773M | XXX | $757M | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 36% | XXX | XXX | XXX |
| EBIT Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| Net Profit | $523M | XXX | $522M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| Net Debt | — | — | $815M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Qiagen Stock Performance
Qiagen has current market cap of $10B, and enterprise value of $11B.
Market Cap Evolution
Qiagen's stock price is $48.81.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11B | $10B | 20.8% | XXX | XXX | XXX | $2.53 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialQiagen Valuation Multiples
Qiagen trades at 5.0x EV/Revenue multiple, and 13.7x EV/EBITDA.
EV / Revenue (LTM)
Qiagen Financial Valuation Multiples
As of April 4, 2026, Qiagen has market cap of $10B and EV of $11B.
Equity research analysts estimate Qiagen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Qiagen has a P/E ratio of 19.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV (current) | $11B | XXX | $11B | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | 13.7x | XXX | 14.0x | XXX | XXX | XXX |
| EV/EBIT | 17.0x | XXX | 17.2x | XXX | XXX | XXX |
| EV/Gross Profit | 7.5x | XXX | 8.2x | XXX | XXX | XXX |
| P/E | 19.2x | XXX | 19.3x | XXX | XXX | XXX |
| EV/FCF | 23.5x | XXX | 23.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Qiagen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Qiagen Margins & Growth Rates
Qiagen's revenue in the last 12 month grew by 6%.
Qiagen's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Qiagen's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Qiagen's rule of X is 52% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Qiagen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 52% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 22% | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Qiagen Public Comps
See public comps and valuation multiples for other Laboratory Services and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Revvity | XXX | XXX | XXX | XXX | XXX | XXX |
| ALS | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| Pro Medicus | XXX | XXX | XXX | XXX | XXX | XXX |
| Bio-Techne | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Qiagen M&A Activity
Qiagen acquired XXX companies to date.
Last acquisition by Qiagen was on XXXXXXXX, XXXXX. Qiagen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Qiagen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialQiagen Investment Activity
Qiagen invested in XXX companies to date.
Qiagen made its latest investment on XXXXXXXX, XXXXX. Qiagen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Qiagen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Qiagen
| When was Qiagen founded? | Qiagen was founded in 1980. |
| Where is Qiagen headquartered? | Qiagen is headquartered in United States. |
| How many employees does Qiagen have? | As of today, Qiagen has over 5K employees. |
| Who is the CEO of Qiagen? | Qiagen's CEO is Thierry Bernard. |
| Is Qiagen publicly listed? | Yes, Qiagen is a public company listed on NYSE. |
| What is the stock symbol of Qiagen? | Qiagen trades under QGEN ticker. |
| When did Qiagen go public? | Qiagen went public in 1996. |
| Who are competitors of Qiagen? | Qiagen main competitors are Revvity, ALS, Bangkok Dusit Medical Services, Pro Medicus. |
| What is the current market cap of Qiagen? | Qiagen's current market cap is $10B. |
| What is the current revenue of Qiagen? | Qiagen's last 12 months revenue is $2B. |
| What is the current revenue growth of Qiagen? | Qiagen revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Qiagen? | Current revenue multiple of Qiagen is 5.0x. |
| Is Qiagen profitable? | Yes, Qiagen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Qiagen? | Qiagen's last 12 months EBITDA is $773M. |
| What is Qiagen's EBITDA margin? | Qiagen's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Qiagen? | Current EBITDA multiple of Qiagen is 13.7x. |
| What is the current FCF of Qiagen? | Qiagen's last 12 months FCF is $451M. |
| What is Qiagen's FCF margin? | Qiagen's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of Qiagen? | Current FCF multiple of Qiagen is 23.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.